Sté Tunisienne des Maladies Respiratoires et d'Allergologie
Cercle des Bureaux - Appartement B 5-3 . 1082 Centre urbain Nord Tunis
RCT: Dapagliflozin in patients with cardiometabolic risk factors hospitalized with COVID-19 – safe, but no statistically significant risk reduction in organ dysfunction or death.
Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial – The Lancet Diabetes & Endocrinology Commentary: Dapagliflozin in patients with COVID-19: truth or dare – The Lancet Diabetes & Endocrinology
The post RCT: Dapagliflozin in patients with cardiometabolic risk factors hospitalized with COVID-19 – safe, but no statistically significant risk reduction in organ dysfunction or death. appeared first on Links Medicus.
-
Taille de police
Réduire la taille de la police
Augmenter la taille de police
About Author
Dernier de Zouhair Souissi
- RCT: ICS-Formoterol and ICS-SABA Reduce Severe Asthma Exacerbations Compared With SABA Alone
- ATS Guideline: Evaluation and Management of Obesity Hypoventilation Syndrome
- RCT: Telehealth-Delivered Early Palliative Care Equivalent to In-Person Care in Advanced Lung Cancer
- Summary: Perioperative Management of Patients Taking Direct Oral Anticoagulants
- Summary: Community-Acquired Pneumonia
Laissez un commentaire
Assurez-vous d'entrer toutes les informations requises, indiquées par un astérisque (*). Le code HTML n'est pas autorisé.